 Mutant APC molecules that lack anticoagulant activity and the associated bleedingcomplications are expected to improve patient survival Bolus dosing of the drug offers more simplified use Exclusively licensed in 2010
[更多]
Resistance, chemo- and radiotherapy
[更多]
- First development of these cyclic polymers- Increases strength of synergistic binding to oligonucleotides- Provides potential to improve gene therapy technologies
[更多]
| |< <- | [6502] [6503] [6504] [6505] [6506] [6507] [6508] [6509] [6510] [6511] [6512] | -> >| |
